Germany’s Federal Court of Justice has dismissed appeals brought by generic drug manufacturers against the validity of a key patent protecting the cancer medication Velcade, JUVE Patent reported.
The X. Civil Senate, led by presiding judge Klaus Bacher, ruled against challenges targeting patent EP 2 251 344 B1 under case ID X ZR 78/24. The decision upholds earlier rulings from the Federal Patent Court, which had dismissed nullity suits filed by Zentiva, Ratiopharm, and Betapharm in April 2024.
Millennium Pharmaceuticals continues to defend the contested patents alongside related patent EP 3 078 667 B1 across multiple European jurisdictions. Market research firm Mordor Intelligence estimates the global market for these therapies at $25.88 billion, with continued growth projected despite the primary patents expiring in January 2022.
The litigation centers on whether clinical trials required for marketing authorization constitute prior art that invalidates subsequent patent protection. Appellants argued that participating clinics failed to maintain adequate confidentiality during the studies.
Clinical Trials and Confidentiality Standards
The Federal Patent Court previously found no evidence that outsiders could extract proprietary details from the clinical trials. Medical staff remained bound by standard confidentiality obligations, and each vial labeled “PS-341” contained just 2.5 mg of active substance—an amount deemed insufficient for meaningful chemical analysis.
Judges also concluded that a skilled person would not have independently arrived at the specific formulation involving lyophilized bortezomib with excess D-mannitol. Research cited by JUVE Patent indicates that the Federal Court of Justice maintains that a legal duty of confidentiality is presumed during such trials, requiring any plaintiff seeking a declaration of nullity to present concrete evidence of a breach.
The appellants must bear the costs of the appeal proceedings, including the expenses incurred by intervener Millennium Pharmaceuticals.
Parallel Proceedings Across Europe
While the patent validity disputes advance in Germany, parallel infringement actions have yielded mixed results across different national courts. The Regional Court Düsseldorf dismissed infringement claims brought by Millennium and Janssen-Cilag against Betapharm, Ratiopharm, Hikma Pharma, Zentiva, and Synthon.
In early 2024, the 4a Civil Chamber presided over by judge Tilmann Büttner ruled that the claimants lacked standing to sue. The court found that the United States, as the official patent owner, had reserved the right to issue additional exclusive licenses, a condition incompatible with an existing exclusive license under German law. The Düsseldorf Higher Regional Court is scheduled to hear the appeal next year.
Conversely, the Paris Judicial Court reached a different conclusion in May during parallel French proceedings. The French court confirmed that Millennium, Janssen, and Cilag possess the legal standing to bring infringement actions because their license agreement explicitly authorizes Millennium to sue in its own name. The Paris court continues to examine the merits, specifically regarding damages tied to price reductions following the entry of generic alternatives.
Additional damages claims remain active in Spain and Italy. Meanwhile, the European Patent Office’s Boards of Appeal upheld the related patent EP 3 078 667 in a limited form in mid-2024.
Legal Representation in German and French Courts
| Party | Legal Representation |
|---|---|
| United States (Patent Owner) / Millennium | Hoyng ROKH Monegier (Christine Kanz, Amandine Métier); Cohausz & Florack (Arwed Burrichter, Natalie Kirchhofer, Wieland Fahr); Christian Rohnke |
| Betapharm | ZSP Patentanwälte (Sebastian Höpfner); Bird & Bird (Roksana Hosseini); Dr. Reddy’s (Mujeebur Rahman) |
| Zentiva | Bird & Bird (Daniela Kinkeldey, Anne Halbach); Zentiva legal (Ana Lopez Lozano) |
| Ratiopharm | Rainer Hall; Graf von Stosch (Sandra Lepthien); Bird & Bird (Oliver Jüngst) |
Disputed Patents Protect Bortezomib Formulations
What active ingredient is protected by the disputed patents?
The patents cover formulations of boronic acid compounds centered on bortezomib, the active ingredient in the anti-cancer medication Velcade used to treat multiple myeloma and mantle cell lymphoma.
Who officially owns the patents involved in the litigation?
The United States of America is the registered owner of patents EP 2 251 344 B1 and EP 3 078 667 B1, while Millennium Pharmaceuticals—operating as Takeda Oncology—acts as the licensee and distributor for the United States.
Founded in Cambridge, Massachusetts in 1993, Millennium Pharmaceuticals is particularly known for bringing Velcade through clinical trials to approval. The biopharmaceutical company was among the first to systematically search for genes linked to disease, and in May 2008, Japanese company Takeda Pharmaceutical announced the completion of its acquisition of Millennium for US$25.00 per share in cash in a deal worth $8.8 billion.
When did the underlying patents expire?
The primary patents expired in January 2022, though Millennium continues to pursue ongoing damages claims against various generics manufacturers across multiple European jurisdictions.
Worth a look
- EU-UK Reset Deal Agreed but Frozen Over Tuition Fee Dispute
- South American Weather Services Advance Regional Observation Network at Argentina Training
- Former Penn State Student Indicted on Federal Cocaine Trafficking Charges (archyworldys.com)
- 2025 ACS Data Show Arizona Families Struggle Before Federal Cuts (news-usa.today)